NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and ...
NextCure, Inc. (NASDAQ: NXTC) is a clinical-stage biopharmaceutical company focused on discovering and advancing novel immunotherapies for cancer and other immune-related diseases. The company’s core mission is to help reactivate normal immune system function to improve treatment outcomes for patients. NextCure’s development strategy centers on immuno-oncology and immunomodulatory biologics designed ...NextCure, Inc. (NASDAQ: NXTC) is a clinical-stage biopharmaceutical company focused on discovering and advancing novel immunotherapies for cancer and other immune-related diseases. The company’s core mission is to help reactivate normal immune system function to improve treatment outcomes for patients. NextCure’s development strategy centers on immuno-oncology and immunomodulatory biologics designed to address key mechanisms of tumor immune evasion.
From a business perspective, NextCure is structured around a pipeline of investigational drug candidates and related preclinical programs, supported by clinical trial execution and scientific validation of target engagement and therapeutic activity. The company operates with a relatively lean operating model—reported as having around 40 employees—typical of early-to-mid clinical development biotechs where external partnerships, clinical sites, and research collaborations help scale activities.
Product and service-wise, NextCure primarily “produces” therapeutic development programs rather than marketed products today. Its lead candidate, NC318, is in Phase II clinical trials for advanced or metastatic solid tumors. Another key program, NC410, is in Phase I studies; it is engineered to counteract immune suppression mediated by LAIR-1 (Leukocyte-Associated Immunoglobulin-like Receptor 1). The company is also advancing immunotherapeutic candidate NC762, which targets B7-H4 (B7 homolog 4), and NC525, a LAIR-1 antibody being evaluated preclinically with an emphasis on acute myeloid leukemia (AML), including activity against blast cells and leukemic stem cells. These programs reflect NextCure’s emphasis on antibody-based immunomedicines and immune pathway modulation.
In terms of costs and financial considerations, clinical-stage biopharmaceutical companies generally face significant R&D spending requirements (clinical trial conduct, manufacturing/CMC for biologics, regulatory and compliance work) and often have limited or no product revenue. The provided financial snapshot indicates negative profitability metrics consistent with a pre-revenue/clinical development phase, alongside liquidity measures such as a relatively strong current ratio.
On key leadership, Michael S. Richman serves as President and Chief Executive Officer and is also credited as a co-founder of NextCure. The company is headquartered in Beltsville, Maryland, and maintains its public-company presence on NASDAQ (Global Select). NextCure was established/incorporated in 2015.
Overall, NextCure’s near- to mid-term “wish list” would naturally involve successful clinical progress of its lead candidates (notably NC318 through Phase II and NC410 through early clinical stages), demonstration of meaningful safety and efficacy signals, and advancement of additional pipeline assets through preclinical-to-clinical transitions—ultimately aiming to build a portfolio of first-in-class or differentiated immunomedicines.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-55.8M
-0.3%
-52.0%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-49.6M
-20.2%
+27.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
14.7%
+62.3%
+91.4%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
4.14x
-44.8%
-24.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
